Mizuho analyst Salim Syed reiterated an Outperform rating and $39.00 price target on Enliven Therapeutics (NASDAQ: ELVN).The analyst commented: "On ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE